- Biomica released impressive pre-clinical data for its rationally designed 4 strand microbiome therapeutic candidate BMC128 in immuno-oncology presented at the 5th Annual European Microbiome Drug Development conference on January 28.
- BMC128 is expected to be tested in human clinical trials in Israel during the second half of this year.
- Microbiome therapeutics are a relatively new area of drug development with novel modes of action for a broad range of treatment indications which is gathering increasing interest and importance.
- Evogene's 90% owned subsidiary Biomica looks very promising. I expect that a Biomica IPO later in 2021 or 2022 may unlock additional value for Evogene's shareholders.
- With a market cap of$225 million, $70 million in cash, no debt, and 4 valuable subsidiaries including Biomica, Evogene is undervalued.
For further details see:
Evogene's Subsidiary Biomica: Impressive Pre-Clinical Data For Its Microbiome Therapeutic BMC128